Companies

Companies

featured image of Lonza Partners with Acumen for Alzheimer's Breakthrough

Lonza Partners with Acumen for Alzheimer’s Breakthrough

BIOT

📰 Lonza teams up with Acumen to make sabirnetug, a groundbreaking Alzheimer's therapy, at their New Hampshire facility. 👥 🧪 Sabirnetug targets toxic amyloid beta oligomers, offering hope in the fight against Alzheimer's. 💡 ⏩ Exciting collaboration to speed up Alzheimer's treatment development. Lonza Acumen AlzheimersTherapy Sabirnetug

featured image of Genmab's $18bn Acquisition Boosts Cancer Pipeline

Genmab’s $18bn Acquisition Boosts Cancer Pipeline

BIOT

💥 Genmab is acquiring ProfoundBio for $1.8bn to expand its pipeline of antibody-drug conjugate therapies. 💊🏭🚀

featured image of FDA Fast Tracks TME Pharma's Glioblastoma Treatment

FDA Fast Tracks TME Pharma’s Glioblastoma Treatment

BIOT

💊 TME Pharma's NOX-A12 gets FDA Fast Track for glioblastoma, aiming to expedite the review and approval process. 🎯

featured image of Forbion Joins Oversubscribed US Financing Rounds

Forbion Joins Oversubscribed US Financing Rounds

BIOT

🇪🇺🚀 European VC firm Forbion joins oversubscribed US financing rounds for Capstan Therapeutics and Engrail Therapeutics 🌍💰 LifeSciences

featured image of Massive Funding Boost for Cultivated Meat Startup

Massive Funding Boost for Cultivated Meat Startup

BIOT

📢 Cultivated meat producer Innocent Meat secures €3m in funding to optimize mass production of stem cell-based meat. 💰🥩🚀🌱

featured image of Synthego Spins Off EditCo Bio for CRISPR Therapy

Synthego Corporation spins out its business into a new company, EditCo Bio

BIOT

📰 Synthego spins off EditCo Bio to deliver edited cells and optimized guide RNA designs for CRISPR therapy. 🔬💼🔀👥

featured image of Spanish Company Acquires ALS Treatment for €1225m

Spanish Company Acquires ALS Treatment for €1225m

BIOT

🇪🇸 Spanish Ferrer Internacional, SA pays €122.5m for ALS candidate, VRG50635, with promising Phase I trial results. 💰🧪

featured image of Novo Nordisk Acquires Cardior Pharmaceuticals for €1025bn Advancing Heart Failure Treatment

Novo Nordisk Acquires Cardior Pharmaceuticals for €1025bn Advancing Heart Failure Treatment

BIOT

📢 Novo Nordisk acquires Cardior Pharmaceuticals for up to €1.025bn! ✨ Exciting Phase II trial for heart failure treatment! ⚙️💡

featured image of Stocks of Chinese Biotechs Plummet as Congress Targets National Security

Stocks of Chinese Biotechs Plummet as Congress Targets National Security

BIOT

📰 Chinese biotech giants WuXi AppTec and WuXi Biologics face stock plunge as US Congress targets national security. 📉🔒

featured image of MilliporeSigma's €300 Million Investment Fuels South Korea's Bioproduction Boom

MilliporeSigma’s €300 Million Investment Fuels South Korea’s Bioproduction Boom

BIOT

📢 MilliporeSigma invests €300 million in South Korea bioproduction site, creating 300 jobs and supporting biotech and pharma industries. 🏭💼🧪🧬